Delaware
|
333-82900
|
94-3018487
|
||
(State or other jurisdiction of incorporation or organization)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
[ ]
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
[ ]
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
[ ]
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
[ ]
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
THERMOGENESIS CORP.,
|
|||
a Delaware Corporation
|
|||
/s/ Matthew T. Plavan
|
|||
Matthew T. Plavan,
|
|||
Chief Executive Officer and Chief Financial Officer
|
|||
Exhibit No.
|
Description
|
|||
99.1
|
Press release dated February 9, 2012, titled “ThermoGenesis Reports Second Quarter Fiscal Year 2012 Results.”
|
|||
·
|
Signing a five-year collaboration with Arthrex, Inc., under which ThermoGenesis, in consultation with Arthrex’s on staff clinicians, has developed two line extensions of Res-Q®, specifically formulated to produce a proprietary composition of platelet rich plasma (PRP) and bone marrow concentrate. Arthrex has global exclusive distribution rights for this proprietary, private-labeled product. The Company expects to record initial revenues from this agreement in its fourth fiscal quarter.
|
·
|
Receiving approval of the AXP® AutoXpress® Platform (AXP) from India’s Ministry of Health.
|
·
|
Being selected by Canadian Blood Services to provide the BioArchive System for a new public cord blood bank that will commence operations a year from now.
|
·
|
Presenting data from Critical Limb Ischemia and long bone fracture clinical evaluations using concentrates prepared by the Res-Q that demonstrate initial positive outcomes.
|
Dial-in (U.S.):
|
1-800-860-2442
|
||
Dial-in (Internationally):
|
1-412-858-4600
|
||
Conference Name:
|
“ThermoGenesis”
|
Access number (U.S.):
|
1-877-344-7529
|
||
Access number (Internationally)
|
1-412-317-0088
|
||
Conference ID#:
|
385107
|
·
|
The BioArchive® System, an automated cryogenic device, used by cord blood stem cell banks in more than 30 countries for cryopreserving and archiving cord blood stem cell units for transplant.
|
·
|
AXP® AutoXpress® Platform (AXP), a proprietary family of automated devices that includes the AXP and the MXP® MarrowXpress® and companion sterile blood processing disposables for harvesting stem cells in closed systems. The AXP device is used for the processing of cord blood. The MXP is used for the preparation of cell concentrates, including stem cells, from bone marrow aspirates in the laboratory setting.
|
·
|
The Res-Q® 60 BMC/PRP (Res-Q), a point-of-care system designed for the preparation of cell concentrates, including stem cells, from bone marrow aspirates and whole blood for platelet rich plasma (PRP).
|
·
|
The CryoSeal® FS System, an automated device and companion sterile blood processing disposable, used to prepare fibrin sealants from plasma in about an hour. The CryoSeal FS System is approved in the U.S. for liver resection surgeries. The CryoSeal FS System has received the CE-Mark which allows sales of the product throughout the European community.
|
THERMOGENESIS CORP.
Condensed Consolidated Balance Sheets
(Unaudited)
|
|||||||
December 31,
2011
|
June 30,
2011
|
||||||
ASSETS
|
|||||||
Current assets:
|
|||||||
Cash and cash equivalents
|
$8,729,000
|
$12,309,000
|
|||||
Accounts receivable, net
|
4,981,000
|
3,963,000
|
|||||
Inventories
|
6,790,000
|
6,348,000
|
|||||
Other current assets
|
170,000
|
420,000
|
|||||
Total current assets
|
20,670,000
|
23,040,000
|
|||||
Equipment
|
1,589,000
|
1,310,000
|
|||||
Other assets
|
48,000
|
49,000
|
|||||
$22,307,000
|
$24,399,000
|
||||||
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
|||||||
Current liabilities:
|
|||||||
Accounts payable
|
$1,648,000
|
$1,791,000
|
|||||
Other current liabilities
|
2,204,000
|
2,273,000
|
|||||
Total current liabilities
|
3,852,000
|
4,064,000
|
|||||
Long-term liabilities
|
227,000
|
242,000
|
|||||
Stockholders’ equity
|
18,228,000
|
20,093,000
|
|||||
$22,307,000
|
$24,399,000
|
THERMOGENESIS CORP.
Condensed Consolidated Statements of Operations
(Unaudited)
|
|||||||||
Three Months Ended,
December 31,
|
Six Months Ended,
December 31,
|
||||||||
2011
|
2010
|
2011
|
2010
|
||||||
Net revenues
|
$4,775,000
|
$5,860,000
|
$9,634,000
|
$12,857,000
|
|||||
Cost of revenues
|
3,071,000
|
3,504,000
|
5,931,000
|
7,906,000
|
|||||
Gross profit
|
1,704,000
|
2,356,000
|
3,703,000
|
4,951,000
|
|||||
Expenses:
|
|||||||||
Selling, general and administrative
|
1,991,000
|
2,333,000
|
4,307,000
|
4,273,000
|
|||||
Research and development
|
1,037,000
|
774,000
|
1,960,000
|
1,499,000
|
|||||
Total operating expenses
|
3,028,000
|
3,107,000
|
6,267,000
|
5,772,000
|
|||||
Interest and other income, net
|
46,000
|
265,000
|
78,000
|
267,000
|
|||||
Net loss
|
($1,278,000)
|
($486,000)
|
($2,486,000)
|
($554,000)
|
|||||
Basic and diluted net loss per common share
|
($0.08)
|
($0.03)
|
($0.15)
|
($0.04)
|
|||||
Shares used in computing per share data
|
16,378,033
|
14,048,649
|
16,370,533
|
14,035,960
|
THERMOGENESIS CORP.
Condensed Consolidated Statements of Cash Flows
(Unaudited)
|
||||||
Six Months Ended
December 31,
|
||||||
2011
|
2010
|
|||||
Cash flows from operating activities:
|
||||||
Net loss
|
($2,486,000)
|
($554,000)
|
||||
Adjustments to reconcile net loss to net
cash used in operating activities:
|
||||||
Depreciation and amortization
|
202,000
|
248,000
|
||||
Stock based compensation expense
|
621,000
|
607,000
|
||||
Gain on disposal of equipment
|
--
|
(7,000)
|
||||
Net change in operating assets and liabilities:
|
||||||
Accounts receivable, net
|
(1,018,000)
|
841,000
|
||||
Inventories
|
(322,000)
|
(622,000)
|
||||
Other current assets
|
130,000
|
80,000
|
||||
Other assets
|
1,000
|
40,000
|
||||
Accounts payable
|
(143,000)
|
(369,000)
|
||||
Other current liabilities
|
(84,000)
|
(782,000)
|
||||
Net cash used in operating activities
|
(3,099,000)
|
(518,000)
|
||||
Cash flows from investing activities:
|
||||||
Capital expenditures
|
(481,000)
|
(35,000)
|
||||
Proceeds from sale of equipment
|
--
|
17,000
|
||||
Net cash used in investing activities:
|
(481,000)
|
(18,000)
|
||||
Cash flows from financing activities:
|
||||||
Exercise of stock options
|
--
|
7,000
|
||||
Payments on capital lease obligations
|
--
|
(1,000)
|
||||
Net cash provided by financing activities
|
--
|
6,000
|
||||
Net decrease in cash and cash equivalents
|
(3,580,000)
|
(530,000)
|
||||
Cash and cash equivalents at beginning of period
|
12,309,000
|
10,731,000
|
||||
Cash and cash equivalents at end of period
|
$8,729,000
|
$10,201,000
|